PT - JOURNAL ARTICLE AU - Rutter, Charlotte E AU - Njoroge, Mary AU - Cooper, Phil AU - Dorairaj, Prabhakaran AU - Jha, Vivekanand AU - Kaur, Prabhdeep AU - Mohan, Sailesh AU - Tatapudi, Ravi Raju AU - Biggeri, Annibale AU - Rohloff, Peter AU - Hathaway, Michelle H AU - Crampin, Amelia AU - Dhimal, Meghnath AU - Poudyal, Anil AU - Bernabe-Ortiz, Antonio AU - O’Callaghan-Gordo, Cristina AU - Chulasiri, Pubudu AU - Gunawardena, Nalika AU - Ruwanpathirana, Thilanga AU - Wickramasinghe, SC AU - Senanayake, Sameera AU - Kitiyakara, Chagriya AU - Gonzalez-Quiroz, Marvin AU - Cortés, Sandra AU - Jakobsson, Kristina AU - Correa-Rotter, Ricardo AU - Glaser, Jason AU - Singh, Ajay AU - Hamilton, Sophie AU - Nair, Devaki AU - Aragón, Aurora AU - Nitsch, Dorothea AU - Robertson, Steven AU - Caplin, Ben AU - Pearce, Neil AU - , TI - International patterns of prevalence of low estimated glomerular filtration rate (eGFR) in population-based surveys of working age adults: The Disadvantaged Populations eGFR Epidemiology Study (DEGREE) AID - 10.1101/2024.06.24.24309380 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.24.24309380 4099 - http://medrxiv.org/content/early/2024/06/24/2024.06.24.24309380.short 4100 - http://medrxiv.org/content/early/2024/06/24/2024.06.24.24309380.full AB - The Disadvantaged populations estimated glomerular filtration rate (eGFR) epidemiology study (DEGREE) was designed to gain insight into the burden of chronic kidney disease (CKD) of undetermined cause (CKDu) using standard protocols to estimate the general-population prevalence of low eGFR internationally.Using population-representative surveys of working-age adults, we estimated the prevalence of eGFR<60mL/min/1.73m2 not due to the common, known causes of CKD by excluding participants with ACR>300mg/g or equivalent, or self-reported or measured hypertension or diabetes (eGFR<60[absent HT, DM, high ACR]). Included studies were either designed to estimate CKDu burden or were re-analyses of large surveys (in areas with reported high CKDu prevalence or proposed risk factors), alongside two high-income reference datasets.There were 61 108 participants from 43 areas across 14 countries. High prevalence of eGFR<60[absent HT, DM, high ACR] (>5%) was generally only observed in rural men, but there were exceptions. Of the areas considered, prevalence in rural men was highest in Andhra Pradesh, India, (14%) and Northwest Nicaragua (14%); it was low (<2%) outside of Central America and South Asia, including areas in Kenya, Italy, Malawi, Peru, Chile, Ecuador, Thailand, England, and the USA.These observations represent the first attempts to quantify the prevalence of eGFR<60[absent HT, DM, high ACR], as an estimate of CKDu burden, around the world. These findings have limitations in terms of comparability of study populations and study timing, lack of individual-level exposure assessment, and absent data in many regions. Although clusters of disease may exist elsewhere, to date the available evidence supports a high general-population burden of CKDu in multiple areas within Central America and South Asia.Competing Interest StatementAB is President of Epidemiologia e Prevenzione, a non-profit social enterprise; PJC has received funding from the National Institute for Health and Care Research (NIHR) (grant 134801); BC has received grants from Kidney Research UK, the Colt foundation and AstraZeneca, has participated on the board of the AstraZeneca ORTIZ study, and has leadership roles in ISN Consortium of CKDu Collaborators (i3C), ISN Western European Board, Consortium for the Epidemic of Nephropathy in Central America and Mexico (CENCAM), and Kidney Research UK Grants Commitee; RCR has received grants from AstraZeneca, Novonordisk, Boehringer Ingelheim, Roche, and Chinook, to his institution, fees for consultancy from AstraZeneca, Novonordisk, Boehringer Ingelheim, Chinook, and Bayer, and honoraria payments from AstraZeneca, Novonordisk, Boehringer Ingelheim, Amgen, and Bayer; SC has received a grant from the NIHR (134801); VJ has received consultancy fees from Bayer, AstraZeneca, Visterra, Chinook, Vera, Biocryst, and Otsuka; DN is the UK Kidney Association Director of Informatics research (unrelated to this work); COCG has received grants from the Universitat Oberta de Catalunya (UOC) and Barcelona Institute for Global Health (ISGlobal); PR received funding from the National Institutes of Health (USA) and is Chief Science Officer of the Maya Health Alliance Guatemala, a community based organization; all other authors declare no competing interests.Funding StatementThis work was funded by grants from the UK Colt Foundation (CF/02/18) and the UK Medical Research Council (MR/P02386X/1 and MR/V033743/1). In addition, individual centres received funding as follows: The study in Chile was supported by the Chilean Agency of Research and Development (ANID), FONDECYT grant 1221680, and FONDAP-MAUCO grant 1523A0008; The study in Ecuador was supported by Universidad Internacional del Ecuador grant EDM-INV-04-19; The study in Guatemala was supported by NIH Grant NIH/FIC 5R21TW010831; The Indian study in Uddanam was supported by a Grand Challenge Award from the Indian Council of Medical Research and the State Government of Andhra Pradesh; The Sri Lankan study was supported by the National Science Foundation of Sri Lanka (RPHS/2016/CKDu 07), the Ministry of Health, Nutrition and Indigenous Medicine and the World Health Organization Country Office Sri Lanka. The study in Italy was supported by the European Union's Horizon 2020 research and innovation programme grant 824484; The Kenyan study was supported by the National Institute for Occupational Safety and Health (NIOSH), Illinois Education and Research Center (ERC) Pilot Project Research Training Grant (T42/OH008672), Environmental and Occupational Health unrestricted global health research funds, Michael Bruton Workplace Safety Foundation Scholarship (2019), UIC Graduate College Award for Graduate Research (2019), Paul Brandt-Rauf Scholarship in Global Health (2018-19), and Donna Farley Global Health Scholarship (2020-21); The UDAY study in India was supported by an unrestricted educational grant from Eli Lilly and Company under the Lilly NCD Partnership Program. The funding agency had no role in the design, conduct or analysis of the study; The Indian study in Prakasam district was supported by the Indian Council of Medical Research, New Delhi; The earlier Nicaraguan study was supported by the Swedish International Agency for Development Cooperation (Sida), through the SAREC project of Bilateral Research Cooperation with UNAN-Leon and the Sida-Health supported SALTRA; The later Nicaraguan study was supported by a grant from the Dutch National Postcode Lottery provided funding to Solidaridad covering a proportion of the fieldwork costs and by the La Isla Network.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the London School of Hygiene and Tropical Medicine gave ethical approval for this work (14704 and 14709)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData from the reference datasets can be found in the public domain: NHANES at https://www.cdc.gov/nchs/nhanes/index.htm and Health Survey England at https://beta.ukdataservice.ac.uk/datacatalogue/series/series?id=2000021. Data for the other included studies may be available by contacting the authors of the respective study papers. https://www.cdc.gov/nchs/nhanes/index.htm https://beta.ukdataservice.ac.uk/datacatalogue/series/series?id=2000021